Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes
Intravitreal Faricimab significantly reduced PED volumes in both treatment-Naïve and non-responder Switch patients over 12 months. The study highlights Faricimab's potential as an effective treatment option for T1 MNV in nAMD, offering significant improvements in PED volume and related fluid biomarkers.
Authors
- Paolo Forte (ORCID: https://orcid.org/0000-0003-1762-3506)
- Chiara Maria Eandi (ORCID: https://orcid.org/0000-0003-3656-1689)
- Giovanni Forte (ORCID: https://orcid.org/0000-0001-5779-9333)
- Jennifer Cattaneo (ORCID: https://orcid.org/0000-0002-3750-2886)
Institutions
- University of Pavia (IT)
- Fondation Asile des Aveugles (CH)
- Torino e-district (IT)
- Ospedale Policlinico San Martino (IT)
- University of Turin (IT)
- University of Genoa (IT)
- University of Lausanne (CH)
Publication Details
- Journal
- International Journal of Retina and Vitreous
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1186/s40942-025-00629-w
- Citations
- 9
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 15.36